Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Published:2013-03 Issue:3 Volume:8 Page:338-345
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Bonomi Philip D.,Mace Joseph,Mandanas Romeo A.,Min Myo,Olsen Mark,Youssoufian Hagop,Katz Terry L.,Sheth Grishma,Lee Hyun Jung

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Management Issues for Stage IV Non-Small Cell Lung Cancer;Earle;Cancer Control,1997

2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials;BMJ,1995

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer;Rosell;Ann Oncol,2008

5. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer;Butts;J Clin Oncol,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress;International Immunopharmacology;2024-01

2. Advances in the Lung Cancer Immunotherapy Approaches;Vaccines;2022-11-19

3. CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW;Experimental Oncology;2022-05-20

4. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-12

5. Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer;Pharmaceutical Medicine;2021-01-23